Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

 
• By Dean Rudge
rebate - cube with letters, sign with wooden cubes
Sandoz continues to wait for a CMS decision on whether two of its products should be classified as innovator drugs. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics